MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Stroke Risk From Raloxifene

Back to breast cancer blog Blogs list Cancer blog  


Subscribe To Breast Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Stroke Risk From Raloxifene

Stroke Risk From Raloxifene
Couple of weeks ago I wrote about Raloxifene (a drug usually used in the prevention of osteoporosis), and discussed a study, which showed significant reduction of breast cancer risk associated with this drug. This drug was hailed as a breakthrough for breast cancer prevention. National Cancer Institute has recently reported that one of the largest breast cancer studies ever done showed that the osteoporosis drug Raloxifene (Evista) is as effective as tamoxifen in the prevention of breast cancer.

Now there are some setbacks uncovering for Raloxifene. But now, Eli Lilly, who makes Raloxifene, says it has uncovered an increased risk of deaths from stroke in users of Raloxifene. This unexpected finding was seen in the course of a study looking for effectiveness of Raloxifene in reducing the risk of heart disease and breast cancer in postmenopausal women.

In this study involving about 10,000 women, scientists found that the incidence of stroke mortality was 1.5 per 1,000 women per year taking a placebo, compared to 2.2 per 1,000 per year for raloxifene according to a warning sent by the company to physicians. However incidence of stroke, myocardial infarction, cardiovascular mortality and overall mortality were comparable between for Raloxifene and placebo which was used in the above said trial.

The company report emphasizes that Raloxifene (Evista) is indicated only for prevention of osteoporosis and should not be used for prevention or risk reduction of heart disease. The drug is currently not approved for breast cancer prevention.

Sherin      




Did you know?
Couple of weeks ago I wrote about Raloxifene (a drug usually used in the prevention of osteoporosis), and discussed a study, which showed significant reduction of breast cancer risk associated with this drug. This drug was hailed as a breakthrough for breast cancer prevention. National Cancer Institute has recently reported that one of the largest breast cancer studies ever done showed that the osteoporosis drug Raloxifene (Evista) is as effective as tamoxifen in the prevention of breast cancer.

Medicineworld.org: Stroke Risk From Raloxifene

BREAST CANCER MAIN| Home| Breast cancer news| Common terms| Breast cancer treatment| Breast cancer treatment by stage| Mammogram and breast cancer screening| Surgical treatment of breast cancer| Chemotherapy of breast cancer| Chemo drugs used in breast cancer| Doxorubicin| Cyclophosphamide| Methotrexate| Hormonal therapy of breast cancer| Radiation therapy of breast cancer| Monoclonal therapy| High dose chemotherapy for breast cancer| Recurrent breast cancer| Bisphosphonates and breast cancer| Pregnancy and breast cancer| Risk factors for breast cancer| Risk details| My risk| Comprehensive breast cancer information| Breast cancer statistics| African Americans and breast cancer| Ashkenazi and breast cancer| Asians| Hispanic| Men| Native Americans| Older women and breast cancer| Younger women| Pregnant women and breast cancer| BRCA|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.